JANX
Janux Therapeutics, Inc.
Next earnings Aug 5, 2026 (after close) · consensus $-0.43 EPS, $12.6M rev
Last earnings -0.5% on 2026-05-07
$14.58
▼ -0.41%$14.58▼ -35.83%
over 1Y
L $12.18EODHDH $34.74
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.4%
1W+3.5%
1M+1.7%
3M+6.1%
YTD+7.3%
1Y-35.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 26 analysts
Buy
Clinical-stage biotech with collapsing cash, accelerating burn, and zero product revenue — speculative binary on early-Phase TRACTr readouts.
Janux is a pre-commercial oncology/autoimmune biotech whose entire $919M market cap rests on early-stage clinical assets — JANX007 (PSMA TRACTr in mCRPC, Phase 1), JANX008 (EGFR TRACTr, Phase 1), and the just-initiated JANX011 (CD19-ARM in healthy volunteers). The company explicitly states it has 'never generated any revenue from product sales' and the $10.0M FY2025 'revenue' is collaboration-related, not commercial — making the 91.9x P/S multiple meaningless as a valuation anchor. With operating margin of -1576.7% and net loss widening 64.7% YoY to -$114M, this is a binary clinical-readout story, not a fundamentals story.
Sources: SEC EDGAR (CIK 0001817713, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/25/2026, 2:40:39 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.